TRCT
NVS icon

Tower Research Capital (TRC)’s Novartis NVS Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,138
Closed -$4.02M – 5424
2025
Q4 		$4.02M Buy
29,138
+27,853
+2,168% +$3.65M 0.1% 181
2025
Q3 		$165K Sell
1,285
-310
-19% -$37.8K ﹤0.01% 1623
2025
Q2 		$193K Buy
1,595
+1,510
+1,776% +$170K 0.01% 1810
2025
Q1 		$9.41K Sell
85
-11,112
-99% -$1.18M ﹤0.01% 3783
2024
Q4 		$1.09M Buy
11,197
+11,095
+10,877% +$1.18M 0.02% 582
2024
Q3 		$11.7K Sell
102
-314
-75% -$35.6K ﹤0.01% 3643
2024
Q2 		$44.3K Sell
416
-3,357
-89% -$337K ﹤0.01% 3193
2024
Q1 		$365K Sell
3,773
-2,814
-43% -$289K 0.01% 1051
2023
Q4 		$665K Buy
6,587
+5,356
+435% +$517K 0.01% 1152
2023
Q3 		$125K Buy
1,231
+1,154
+1,499% +$117K ﹤0.01% 1808
2023
Q2 		$7.77K Sell
77
-23
-23% -$2.3K ﹤0.01% 4529
2023
Q1 		$9K Sell
100
-1,394
-93% -$122K ﹤0.01% 4517
2022
Q4 		$135K Buy
1,494
+343
+30% +$28.9K 0.01% 1594
2022
Q3 		$87K Sell
1,151
-9,060
-89% -$751K ﹤0.01% 2683
2022
Q2 		$863K Buy
10,211
+7,594
+290% +$666K 0.02% 791
2022
Q1 		$229K Sell
2,617
-7,598
-74% -$658K ﹤0.01% 1634
2021
Q4 		$894K Buy
10,215
+10,015
+5,008% +$832K 0.02% 755
2021
Q3 		$16K Sell
200
-6,246
-97% -$562K ﹤0.01% 3934
2021
Q2 		$588K Sell
6,446
-1,564
-20% -$139K 0.02% 1052
2021
Q1 		$685K Buy
8,010
+7,810
+3,905% +$701K 0.01% 990
2020
Q4 		$19K Sell
200
-4,227
-95% -$369K ﹤0.01% 3902
2020
Q3 		$385K Buy
+4,427
New +$384K ﹤0.01% 1969
2020
Q2 		– Sell
-4,388
Closed -$362K – 4908
2020
Q1 		$362K Buy
4,388
+3,152
+255% +$281K 0.02% 547
2019
Q4 		$117K Sell
1,236
-728
-37% -$65.3K 0.01% 841
2019
Q3 		$171K Buy
1,964
+1,679
+589% +$151K 0.01% 1079
2019
Q2 		$26K Sell
285
-1,162
-80% -$98.3K ﹤0.01% 2010
2019
Q1 		$125K Buy
1,447
+928
+179% +$74.5K 0.01% 1334
2018
Q4 		$40K Sell
519
-1,171
-69% -$91.2K ﹤0.01% 1434
2018
Q3 		$130K Sell
1,690
-2,099
-55% -$155K 0.01% 1204
2018
Q2 		$257K Buy
3,789
+940
+33% +$64.9K 0.01% 958
2018
Q1 		$206K Buy
+2,849
New +$217K 0.02% 865
2017
Q4 		– Sell
-7
Closed -$1K – 3847
2017
Q3 		$1K Sell
7
-4,517
-100% -$341K ﹤0.01% 3667
2017
Q2 		$338K Buy
4,524
+2,115
+88% +$150K 0.04% 254
2017
Q1 		$160K Buy
2,409
+2,001
+490% +$133K 0.02% 339
2016
Q4 		$27K Buy
408
+6
+1% +$389 ﹤0.01% 1885
2016
Q3 		$28K Sell
402
-926
-70% -$67.5K ﹤0.01% 1426
2016
Q2 		$98K Buy
+1,328
New +$91.7K 0.01% 1115
2015
Q4 		– Sell
-1,984
Closed -$163K – 4881
2015
Q3 		$163K Sell
1,984
-433
-18% -$38.5K 0.02% 342
2015
Q2 		$213K Buy
2,417
+1,524
+171% +$140K 0.02% 340
2015
Q1 		$79K Buy
+893
New +$79.2K 0.01% 1092
2014
Q4 		– Sell
-1,192
Closed -$101K – 4478
2014
Q3 		$101K Buy
1,192
+1,130
+1,823% +$91.4K 0.01% 935
2014
Q2 		$5K Sell
62
-88
-59% -$6.92K ﹤0.01% 2862
2014
Q1 		$12K Sell
150
-1,110
-88% -$80.9K ﹤0.01% 2430
2013
Q4 		$91K Buy
1,260
+781
+163% +$54.3K 0.02% 917
2013
Q3 		$33K Buy
479
+460
+2,421% +$30.4K ﹤0.01% 2281
2013
Q2 		$1K Buy
+19
New +$1.24K ﹤0.01% 3709

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tower Research Capital (TRC)'s NVS Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Novartis (NVS) in Q1 2026, closing a stake of 29,138 shares — an estimated $4.02M sold.

Tower Research Capital (TRC) first reported a position in NVS in Q2 2013 and held it in 46 quarters. The position peaked at $4.02M in Q4 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 29,138 Novartis shares in Q1 2026, an estimated $4.02M.
  • Tower Research Capital (TRC) first reported a position in Novartis in Q2 2013 and held it in 46 quarters.
  • Tower Research Capital (TRC)'s Novartis position peaked at $4.02M in Q4 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.